Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals

被引:18
|
作者
Clausen, Louise Nygaard [1 ,3 ,4 ]
Astvad, Karen [2 ]
Ladelund, Steen [3 ]
Larsen, Mette Vang
Schonning, Kristian [2 ]
Benfield, Thomas [3 ]
机构
[1] Copenhagen Univ Hosp, Copenhagen Hepatitis C Program CO HEP, Dept Infect Dis, DK-2650 Hvidovre, Denmark
[2] Copenhagen Univ Hosp, Dept Clin Microbiol, DK-2650 Hvidovre, Denmark
[3] Copenhagen Univ Hosp, Clin Res Ctr, DK-2650 Hvidovre, Denmark
[4] Univ Copenhagen, Fac Hlth Sci, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark
基金
英国医学研究理事会;
关键词
chronic inflammation; disease burden; HIV exposure group; time-updated survival analysis; IMMUNODEFICIENCY-VIRUS-INFECTION; INJECTION-DRUG USERS; STAGE LIVER-DISEASE; NATURAL-HISTORY; HEMOPHILIC PATIENTS; HCV GENOTYPE; PROGRESSION; IMPACT; COHORT; ASSOCIATION;
D O I
10.1097/QAD.0b013e3283553581
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: We hypothesized that hepatitis C virus (HCV) load and genotype may influence all-cause mortality in HIV-HCV-coinfected individuals. Design and methods: Observational prospective cohort study. Mortality rates were compared in a time-updated multivariate Poisson regression analysis. Results: We included 264 consecutive HIV-HCV-coinfected individuals. During 1143 person years at risk (PYR) 118 individuals died [overall mortality rate 10 (95% confidence interval; 8, 12)/100 PYR]. In multivariate analysis, a 1 log increase in HCV viral load was associated with a 30% higher mortality risk [adjusted mortality rate ratio (aMRR): 1.30 (1.10,1.54)] when adjusted for sex, age, HIV exposure group, CD4 cell count, HIV RNA, HCV genotype and interleukin (IL)-28B genotype. Further, HCV genotype 3 vs. 1 [aMRR: 1.83 (1.12, 2.98)] and HIV RNA [aMRR: 3.14 (1.37,7.17) for undetectable vs. just detectable HIV RNA] were independent predictors of mortality, whereas a higher CD4 cell count was associated with a 41% reduction in mortality rate per 50 cell increase between 0 and 200 cells/mu l [aMRR: 0.59 (0.48, 0.72)] and a 10% reduction for increases above 200 cells/mu l [aMRR: 0.90 (0.82-0.98)]. IL28B) CC genotype was associated with 54% higher mortality risk [aMRR: 1.54 (0.89, 3.82] compared to TT genotype. Conclusion: High-HCV viral load, HCV genotype 3 and IL28B genotype CC had a significant influence on the risk of all-cause mortality among individuals coinfected with HIV-1. This may have consequences for the management of HIV-HCV-coinfected individuals. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:1509 / 1516
页数:8
相关论文
共 50 条
  • [31] Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1
    Huang, Chung-Feng
    Yeh, Ming-Lun
    Huang, Jee-Fu
    Yang, Jeng-Fu
    Hsieh, Ming-Yen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Wang, Liang-Yen
    Hsi, Edward
    Juo, Suh-Hang Hank
    Dai, Chia-Yen
    Chuang, Wan-Long
    Yu, Ming-Lung
    ANTIVIRAL RESEARCH, 2012, 93 (02) : 239 - 244
  • [32] Interleukin-28B polymorphism and ITPA gene variations in hepatitis C genotype 1 patients treated with pegylated interferon and ribavirin
    Vsm, Ekstr M.
    Kumar, R.
    Zhao, Y.
    Yee, M. L.
    Chow, W. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 383 - 383
  • [33] Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response
    Asahina, Yasuhiro
    Nakagawa, Mina
    Kakinuma, Sei
    Watanabe, Mamoru
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2013, 1 (01) : 39 - 44
  • [34] Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection
    Kitson, Matthew T.
    George, Jacob
    Dore, Gregory J.
    Leung, Reynold
    Button, Peter
    McCaughan, Geoffrey W.
    Crawford, Darrell H. G.
    Sievert, William
    Weltman, Martin D.
    Cheng, Wendy S. C.
    Roberts, Stuart K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (07) : 1458 - 1462
  • [35] INTERLEUKIN-28B PREDICTS SVR IN LATIN AMERICAN HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH PEG IFN AND RIBAVIRIN
    Ridruejo, E.
    Solano, A.
    Delettieres, D.
    Martinez, A.
    Marciano, S.
    Mando, O. G.
    Galdame, O.
    Gadano, A.
    Silva, M. O.
    Adrover, R.
    Cocozzella, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S465 - S465
  • [36] Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B
    Dahari H.
    Guedj J.
    Perelson A.S.
    Layden T.J.
    Current Hepatitis Reports, 2011, 10 (3) : 214 - 227
  • [37] Natural Killer Inhibitory Receptor Expression Associated with Treatment Failure and Interleukin-28B Genotype in Patients with Chronic Hepatitis C
    Golden-Mason, Lucy
    Bambha, Kiran M.
    Cheng, Linling
    Howell, Charles D.
    Taylor, Milton W.
    Clark, Paul J.
    Afdhal, Nezam
    Rosen, Hugo R.
    HEPATOLOGY, 2011, 54 (05) : 1559 - 1569
  • [38] Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients
    Degasperi, Elisabetta
    Valenti, Luca
    Aghemo, Alessio
    De Francesco, Raffaele
    Rumi, Mariagrazia
    Soffredini, Roberta
    Donnici, Lorena
    Cheroni, Cristina
    Fargion, Silvia
    Zanoni, Valeria
    Orsi, Emanuela
    Colombo, Massimo
    ANTIVIRAL THERAPY, 2014, 19 (08) : 747 - 753
  • [39] Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a
    Yamada, Keiichi
    Ishigami, Masatoshi
    Kuzuya, Teiji
    Honda, Takashi
    Hayashi, Kazuhiko
    Goto, Hidemi
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (08) : 1361 - 1367
  • [40] HLA-G liver expression in chronically HIV/hepatitis C-coinfected individuals.
    Vilar, Fernando Crivelenti
    Donadi, Eduardo
    da Fonseca, Benedito Antonio Lopes
    Freitas, Janaina Cristiana de Oliveira Crispim
    Borducchi, Ana Leticia Gomide Zanin
    Santana, Rodrigo de Carvalho
    ANNALS OF HEPATOLOGY, 2025, 30 (01)